中国医药指南
中國醫藥指南
중국의약지남
Guide of China Medicine
2015年
27期
24-24,25
,共2页
美沙拉嗪%柳氮磺吡啶%溃疡性结肠炎
美沙拉嗪%柳氮磺吡啶%潰瘍性結腸炎
미사랍진%류담광필정%궤양성결장염
Mesalazine%Sulfasalazine%Ulcerative colitis
目的:对比观察美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的疗效及安全性。方法研究对象为2011年1月至2014年8月进行治疗的溃疡性结肠炎患者88例,随机分为治疗组、对照组。基础治疗基础上治疗组饭前1 h口服美沙拉嗪片,0.5克/次,3次/天。对照组口服柳氮磺胺吡啶片,起始剂量0.5~1克/次,3~4次/天,总剂量<3 g/d。治疗一段时间若无明显不良反应,则4~6 g/d,症状缓解后可逐渐减量至1.5~2 g/d维持治疗。两组均治疗8周。结果两组治疗后结肠黏膜组织学评分与同组内治疗前比较差异有统计学意义(P<0.05),两组间比较差异无统计学意义(P>0.05)。治疗组总有效率为95.45%,对照组总有效率为75.00%,两组比较差异有统计学意义(P<0.05)。治疗组出现恶心1例,不良反应发生率为2.27%;对照组出现恶心4例,皮疹4例,不良反应发生率为18.18%。两组比较差异有统计学意义(P<0.05)。结论美沙拉嗪治疗溃疡性结肠炎比柳氮磺吡啶疗效好,且安全性更高。
目的:對比觀察美沙拉嗪與柳氮磺吡啶治療潰瘍性結腸炎的療效及安全性。方法研究對象為2011年1月至2014年8月進行治療的潰瘍性結腸炎患者88例,隨機分為治療組、對照組。基礎治療基礎上治療組飯前1 h口服美沙拉嗪片,0.5剋/次,3次/天。對照組口服柳氮磺胺吡啶片,起始劑量0.5~1剋/次,3~4次/天,總劑量<3 g/d。治療一段時間若無明顯不良反應,則4~6 g/d,癥狀緩解後可逐漸減量至1.5~2 g/d維持治療。兩組均治療8週。結果兩組治療後結腸黏膜組織學評分與同組內治療前比較差異有統計學意義(P<0.05),兩組間比較差異無統計學意義(P>0.05)。治療組總有效率為95.45%,對照組總有效率為75.00%,兩組比較差異有統計學意義(P<0.05)。治療組齣現噁心1例,不良反應髮生率為2.27%;對照組齣現噁心4例,皮疹4例,不良反應髮生率為18.18%。兩組比較差異有統計學意義(P<0.05)。結論美沙拉嗪治療潰瘍性結腸炎比柳氮磺吡啶療效好,且安全性更高。
목적:대비관찰미사랍진여류담광필정치료궤양성결장염적료효급안전성。방법연구대상위2011년1월지2014년8월진행치료적궤양성결장염환자88례,수궤분위치료조、대조조。기출치료기출상치료조반전1 h구복미사랍진편,0.5극/차,3차/천。대조조구복류담광알필정편,기시제량0.5~1극/차,3~4차/천,총제량<3 g/d。치료일단시간약무명현불량반응,칙4~6 g/d,증상완해후가축점감량지1.5~2 g/d유지치료。량조균치료8주。결과량조치료후결장점막조직학평분여동조내치료전비교차이유통계학의의(P<0.05),량조간비교차이무통계학의의(P>0.05)。치료조총유효솔위95.45%,대조조총유효솔위75.00%,량조비교차이유통계학의의(P<0.05)。치료조출현악심1례,불량반응발생솔위2.27%;대조조출현악심4례,피진4례,불량반응발생솔위18.18%。량조비교차이유통계학의의(P<0.05)。결론미사랍진치료궤양성결장염비류담광필정료효호,차안전성경고。
ObjectiveTo compare and observe the curative effect and safety of beautifulsalad diazoxide and sulfasalazine in treatment of ulcerative colitis. MethodsThe study object for the 2011 January-2014 year in August to 88 in patients with ulcerative colitis treated patients, randomly divided into treatment group, control group. Foundation treatment on the basis of the treatment group before 1h oral mesalazinetablets, 0.5 g/times, 3 times/d. The control group oral sulfasalazine, initial dose of 0.5-1 g/, 3- 4 times/d, a total dose <3 g/d. Treatment for a period of time withoutobvious adverse reactions, 4-6 g/d, alleviate symptoms can be gradually reduced to1.5-2 g/d maintenance therapy. The two groups were treated for 8 weeks.ResultsOf the two groups after treatment of colonic mucosal histology scorecompared with the treatment in the same group before the difference was statistically signiifcant (P<0.05). The total effective rate and of the incidence rate of adverse reaction of treatment group were 95.45% and 2.27%, and of the control group were 75.00% and 18.18%(P<0.05). ConclusionMesalazine on ulcerative colitiscurative effect of sulfasalazine, and higher safety.